Tirzepatide is a once-weekly injectable dual glucagon-like peptide 1 (GLP-1) receptor and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist
At the Florida Surgery & Weight Loss Center , our expertise is accessible to you across Maryland via secure, licensed telehealth services
"Dual GIP and GLP-1 receptor agonist tirzepatide alleviates hepatic steatosis and modulates gut microbiota and bile acid metabolism in diabetic mice" Int Immunoph PubMed Tirzepatide is a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors and is a promising therapeutic option for type 2 diabetes mellitus (T2DM)
In early animal studies (specifically in rats and mice), semaglutide was associated with an increased risk of a rare type of thyroid cancer called Medullary Thyroid Carcinoma (MTC)
Once you achieve that, set the next goal (maybe 10%)
Originally introduced as a treatment for type 2 diabetes, Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) quickly gained widespread popularity after the FDA approved semaglutide for weight management